GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Navco Pharmaceuticals Inc (TSXV:NAV) » Definitions » Earnings Yield (Joel Greenblatt) %

Navco Pharmaceuticals (TSXV:NAV) Earnings Yield (Joel Greenblatt) % : -11.52% (As of Mar. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Navco Pharmaceuticals Earnings Yield (Joel Greenblatt) %?

Navco Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2023 was C$0.46 Mil. Navco Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was C$-0.05 Mil. Navco Pharmaceuticals's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2023 was -11.52%.

The historical rank and industry rank for Navco Pharmaceuticals's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

TSXV:NAV' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4.59   Med: 0   Max: 0
Current: -3.46

TSXV:NAV's Earnings Yield (Joel Greenblatt) % is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.53 vs TSXV:NAV: -3.46

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Navco Pharmaceuticals's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Navco Pharmaceuticals Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Navco Pharmaceuticals's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navco Pharmaceuticals Earnings Yield (Joel Greenblatt) % Chart

Navco Pharmaceuticals Annual Data
Trend Jun18 Jun19 Jun20 Jun21
Earnings Yield (Joel Greenblatt) %
- -33.00 -18.98 -17.86

Navco Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.55 -22.08 -20.33 -14.99 -11.52

Competitive Comparison of Navco Pharmaceuticals's Earnings Yield (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Navco Pharmaceuticals's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Navco Pharmaceuticals's Earnings Yield (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Navco Pharmaceuticals's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Navco Pharmaceuticals's Earnings Yield (Joel Greenblatt) % falls into.



Navco Pharmaceuticals Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Navco Pharmaceuticalss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Jun. 2021 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-0.08/0.448
=-17.86 %

Navco Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.05 Mil.



Navco Pharmaceuticals  (TSXV:NAV) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Navco Pharmaceuticals Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Navco Pharmaceuticals's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Navco Pharmaceuticals (TSXV:NAV) Business Description

Traded in Other Exchanges
N/A
Address
1055 West Georgia Street, Suite 1500, Vancouver, BC, CAN, V6E 4N7
Website
Navco Pharmaceuticals Inc uses of nanotechnology to develop and commercialize novel products to protect against viruses, bacteria, and infectious diseases. The company's pipeline of applications is tailored to defend against pathogens utilizing new methods of action to capitalize on unmet product needs using natural & known compounds, nanoparticles, and no chemicals with a high degree of efficacy. Its target markets include human health & personal skin care, household & institutional products, and veterinary health.